New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction

Abstract

Get full access to this article

View all access options for this article.

References

Sadovsky R , Miller T , Moskowitz M , Hackett G. Three-year update of sildenafil citrate (Viagra) efficacy and safety . Int J Clin Pract 2001;55(2): 115-128

Padma-Nathan H , Giuliano F. Oral drug therapy for erectile dysfunction . Urol Clin North Am 2001;28(2): 321-334

Lue TF. Erectile dysfunction . N Eng J Med 2000;342: 1802-1813

Lin CS , Xin ZC , Lin G , Lue TF. Phosphodiesterases as therapeutic targets . Urology 2003;61(4): 685-691

Sairam K , Kulinskaya E , McNicholas TA , Boustead GB , Hanbury DC. Sildenafil influences lower urinary tract symptoms . BJU Int 2002;90: 836-839

Brock G , McMahon CG , Chen KK , Costigan T , Shen W , Watkins V , et al . Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses . J Urol 2002;168: 1332-1336

Saenz de Tejada I , Angulo J , Cuevas P , Fernandez A , Moncada I , Allona A , et al . The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil . Int J Impot Res 2001;13: 282-290

Patterson B , Bedding A , Jewell H , Payne C , Mitchell M. The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil . Int J Impot Res 2001;13(Suppl4): A120